Search results
Anticoagulation for Stroke Prevention
Author(s):
Amit Mistri
Start date:
Apr 02, 2015
Broadcast
Author(s):
Oliver Plunkett
,
Gregory YH Lip
Added:
3 years ago
The introduction of novel oral anticoagulants (NOACs) has widened the treatment options for oral anticoagulation in stroke prevention in non-valvular atrial fibrillation (AF). Guidelines for the management of non-valvular AF have changed to reflect the emerging evidence of their relative safety and efficacy compared with warfarin (see Table 1).1–6
Download original
NOACs are now licensed for…
View more
Author(s):
Sunil Kapur
,
Moussa Mansour
Added:
3 years ago
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting more than three million Americans.1 The management of AF revolves around the alleviation of symptoms related to an accelerated and irregular ventricular response, and the prevention of cardioembolism, notably stroke. In patients with AF, there is a fivefold increased incidence of embolic stroke.2 The prevention of systemic…
View more
Author(s):
Katrina Mountfort
,
A John Camm
,
Gregory YH Lip
,
et al
Added:
3 years ago
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is characterised by rapid and irregular heart rates. It is a lifethreatening condition present in up to 1.5 % of the population and accounts for approximately 15 % of all stroke events.1 While relatively unusual in those under 55 years, its incidence increases substantially with age, particularly between the ages of 65…
View more
Author(s):
Tze-Fan Chao
,
Chern-En Chiang
,
Shih-Ann Chen
Added:
3 years ago
Burden of Atrial Fibrillation
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, accounting for approximately one-third of hospitalisations for cardiac rhythm disturbances.1 Between 1980 and 2000, the age-adjusted incidence of AF significantly increased from 3.04 to 3.68 per 1,000 person-years in the US.2 The prevalence of AF was lower among African Americans…
View more
Author(s):
Dhiraj Gupta
,
Hugh Calkins
Added:
3 years ago
In this peer-to-peer discussion, Prof Dhiraj Gupta, Liverpool Heart and Chest Hospital, and Dr Hugh Calkins, Johns Hopkins Medicine, summarise the AF-related updates to the European guidelines, discuss the studies that have underpinned the changes, and consider the NOAC choices for pericatheter ablation, the utilisation of NOACs with and without interruption, and the length of anticoagulation…
View more
Added:
3 years ago
Dr Nazem Akoum (Washington, WA) discusses whether atrial fibrosis and associated atrial cardiopathy may be in the causal pathway of cardioembolic stroke independently of atrial fibrillation. He also sheds light on what further studies are needed in follow-up to these results.
Questions:
1. What clinical problem does this study aim to address?
2. What was your hypothesis?
3. What was the…
View more
Author(s):
Michael C Gibson
Added:
5 years ago
Dr C. Michael Gibson (Beth Israel Deaconess Medical Center, Boston, MA, US) discusses Rivaroxaban 2.5 mg BID combined with DAPT for the prevention of death/MI/stroke - a patient level data meta-analysis of the ATLAS-ACS-2 TIMI-51 and the COMMANDER HF trials
Filmed on site at CRT 2019 by Radcliffe Cardiology
Questions:
1. Why did you conduct this analysis?
2. How was data collected and…
View more
Author(s):
Michala Sejr
Added:
5 years ago
Dr Michala Sejr (Institut for Klinisk Medicin, Herning, DK) discusses comparison of simultaneous two-day external loop recording and Holter monitor recording for detection of atrial fibrillation in patients after acute ischemic stroke or transient ischemic attack
Filmed by Radcliffe Cardiology on-site at ESC 2018
View more
Author(s):
George D Katritsis
,
Demosthenes G Katritsis
Added:
3 years ago
Atrial fibrillation (AF) is associated with a fivefold increased risk for stroke, a twofold increased risk for dementia, and a tripling of risk for heart failure,1,2,3 while AF genetic risk is strongly associated with cardioembolic stroke.4In the Framingham Heart Study the percentage of strokes attributable to AF increases steeply from 1.5% at 50–59 years of age to 23.5% at 80−89 years of age.5,6…
View more